|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> >> 市场分析报告 |
市场分析报告 |
|
Targeted Protein Degradation Market by Type [PROTACs (Vepdegestrant, Bavdegalutamide), SERDs (Elacestrant), Molecular Glues (Mezigdomide), LDD, LYTAC/ATAC], Indication (Oncology, Inflammatory), Formulation (Oral), End User - Global Forecast to 2035 ... [molecular glue (mezigdomide, Iberdomide), SERDs (Elacestrant, Giredestrant, Camizestrant), PROTAC (Vepdegestrant, Bavdegalutamide ... Selective estrogen receptor degraders - Pipeline Insight, 2022 ... Degraders Emerging Drugs Elacestrant: Radius Health Elacestrant is a selective estrogen ... active-controlled study evaluating elacestrant as second- or third-line monotherapy ... Therapeutics Evestra Key Products Elacestrant Giredestrant OP 1250 LY 3484356 RG ... Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market - 2025 -2033 ... estrogen receptor degraders (SERDs), such as elacestrant (Orserdu), has created a significant ... switching to effective therapies. The approval of elacestrant by the FDA in January 2023 ... ESR1-targeted therapies like elacestrant (approved by the FDA). The co- ... Metastatic Breast Cancer Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type ... -optimization. Others: Encompassing endocrine like elacestrant for ESR1-mutated and Trop ... TNBC footprint. Menarini Group: Orserdu (elacestrant) targets ESR1, carving endocrine resistance ... Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer- Market Insights, Epidemiology and Market Forecast–2028 This report can be delivered to the clients within 24 hours DelveInsight’s ‘Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer- Market Insights, Epidemiology and Market Forecast–2028 report delivers an in-depth ... United States Breast Cancer Therapeutics Market, By Therapy {Chemotherapy (Anthracyclines, Taxanes, Antimetabolites, and Others), Hormone Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Others), Immunotherapy, Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitor, Herceptin, and Others), and Others}, By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others), and By Region, Competition, Forecast & Opportunities, 2028 ... development. The entirely novel medication elacestrant occupies an important void in the market ... Global Selective Estrogen Receptor Degrader (SERDs) Market Opportunity, Generic Availability, Drug Dosage, Price & Clinical Trials Insight 2030 ... in 2023 with FDA approval of Orserdu (elacestrant), which was originally developed by Radius ... Radius Health Inc (RDUS) - Financial and Strategic SWOT Analysis Review ... for postmenopausal women with osteoporosis; elacestrant (RAD1901) for estrogen-receptor (ER)-positive ... |